

Product Datasheet

SB-204990

Catalog No. **BP-01898** · CAS **154566-12-8** · Form **free base** · Physical state **solid** · Color **White to off-white** · Version **1.0** · Revision **2026-09-04**


FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target ATP Citrate Lyase	Research area Metabolic Disease
------------------------------------	---

Molecular formula **C₁₈H₂₂Cl₂O₅**

Molecular weight **389.2700**

STRUCTURE



DESCRIPTION

SB 204990 is a potent and specific inhibitor of ATP citrate lyase (ACLY) enzyme.

BIOLOGICAL ACTIVITY

In Vitro

SB204990 (SB) is a specific inhibitor of ACLY enzyme. SB204990 treatment leads to a decrease in cytosolic Ac-CoA level and is thus expected to decrease acetylated and active β -catenin levels.

In Vivo

SB 204990, when administered orally to rats, is absorbed into the systemic circulation. When administered in the diet (0.05-0.25%, w/w) for 1 week, SB 204990 causes a dose-related decrease in plasma cholesterol (by up to 46%) and triglyceride levels (by up to 80%) in rats. SB 204990 (25 mg/kg per day) also decreases plasma cholesterol levels (by up to 23%) and triglyceride levels (by up to 38%) in the dog, preferentially decreasing low-density lipoprotein compared with high-density lipoprotein cholesterol levels.

SOLUBILITY

Soluble in DMSO : ≥ 100 mg/mL H₂O : 25 mg/mL

REFERENCES

- [1]. Shares BH, et al. Active mitochondria support osteogenic differentiation by stimulating β -catenin acetylation. J Biol Chem. 2018 Oct 12;293(41):16019-16027.
- [2]. Pearce NJ, et al. The role of ATP citrate-lyase in the metabolic regulation of plasma lipids. Hypolipidaemic effects of SB-204990, a lactone prodrug of the potent ATP citrate-lyase inhibitor SB-201076. Biochem J. 1998 Aug 15;334 (Pt 1):113-9.

Tel: +86 20 31130026 · Fax: +86 20 36822386 · tech@biochemprobe.com · www.biochemprobe.com

BiochemProbe is the catalog brand of Guangzhou Yuyuan Biotech Co., Ltd. · For research use only.

Lot CoA and SDS are separate documents.